Benchling Inc., of San Francisco, said it closed a $34.5 million series C funding led by Menlo Ventures with new investors Lead Edge Capital and Y Combinator Continuity and returning investors Benchmark and Thrive Capital. 

Alexion Pharmaceuticals Inc., of Boston, reported second-quarter revenues of $1.2 billion, a 15% increase compared to $1 billion in the same period last year. 

The FDA's Arthritis Advisory Committee (AAC) Thursday will consider a supplemental new drug application for Boehringer Ingelheim GmbH's Ofev (nintedanib) capsules as a treatment for systemic sclerosis-associated interstitial lung disease (SSc-ILD). 

Pluristem Therapeutics Inc., of Haifa, Israel, declared a 1-for-10 reverse stock split, effective as of the market opening on Thursday. 

Iovance Biotherapeutics Inc., of San Carlos, Calif., appointed Friedrich Graf Finckenstein chief medical officer.

X-vax Technology Inc., of Jupiter, Fla., raised $56 million in an upsized series A financing with participation from strategic and institutional investors, including JJDC Inc., Adjuvant Capital, Serum Institute of India, Alexandria Venture Investments and FF DSF VI, a scout investment vehicle out of Founders Fund. 

Exscientia Ltd., of Oxford, U.K., an artificial intelligence-driven drug discovery company, said it entered a collaboration with Rallybio Inc., of Farmington, Conn., to accelerate the discovery of small-molecule drug therapeutics for undisclosed rare disease indications.